KRAS and non-small cell lung carcinoma: Interestingly, in a KRAS-driven non-small cell lung cancer mouse model, ERK-induced concomitant upregulation of Ccnd1, as well as Ccnd3, was observed, rendering the tumor resistant to palbociclib [46].